L. Bodnar, M. Gornas and C. Szczylik, “Sorafenib as a Third Line Therapy in Patients with Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Phase II Study,” Gynecologic Oncology, Vol. 123, No. 1, 2011, pp. 33-36. doi:10.1016/j.ygyno.2011.06.019

has been cited by the following article:

• TITLE: Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

  AUTHORS: Nicoletta Staropoli, Cirino Botta, Domenico Ciliberto, Lucia Fiorillo, Antonina Maria De Angelis, Caterina Viscomi, Simona Gualtieri, Angela Salvino, Pierfrancesco Tassone, Pierosandro Tagliaferri

  KEYWORDS: Ovarian Cancer; Systemic Chemotherapy; Platinum Sensitivity Status

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.5, July 9, 2013

  ABSTRACT: Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional drugs was confirmed in different trials without a significant impact in terms of overall survival. In the last years particular emphasis was given to targeted anti-angiogenetic therapy which produced a survival improvement with an acceptable toxicity profile. New “ad hoc” approaches, with a major attention to outcome-predictive factors, are eagerly awaited.